Skip to content
value.today

Pressure Biosciences Inc.

Formerly BOSTON BIOMEDICA INC

Total raised
$28 M
5 rounds on record
Latest round
$17 M
May 2018
First round on record
Feb 2009
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pressure Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$17 MNo. 5$10 to $50 million

Pressure Biosciences Inc.: Raise no. 5, May 2018

Investors in this round

43 investors had bought by the notice of Mar 20, 2019: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
$1 million to $5 million
Sales commissions
$416,300
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Richard P. Thomley · Executive Officer · Acting Chief Financial Officer
  • Richard T. Schumacher · Executive Officer, Director · President, Chief Executive Officer, Treasurer and Clerk
  • Jeffrey N. Peterson · Director · Chairman of the Board
  • Kevin A. Pollack · Director
  • Michael S. Urdea · Director · Chairman of the Board
  • Vito J. Mangiardi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Garden State Securities, Inc. · Red Bank, New JerseySold in all US states

Remarks in the notice

  • On fees: “Warrants for 318,680 shares with an exercise price of $3.50 per share were issued to Garden State as compensation in addition to their sales commissions.”
  • On the amounts: “From May 2, 2018 through March 6, 2019, the Company sold the securities detailed in Item 9 for a total purchase price of $4,288,000. During the same period, the company converted debt equal to $13,171,551 into the securities detailed in Item 9.”

Signed by Richard T. Schumacher, President, CEO, Treasurer, Clerk and Director. Source: SEC Form D, newest notice filed Mar 20, 2019. Read the notice at the SEC.

equity, optionsSEC
Jul 2015$5 MNo. 4$2 to $10 million

Pressure Biosciences Inc.: Raise no. 4, Jul 2015

Investors in this round

22 investors had bought by the notice of Jan 27, 2016: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$460,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Richard Schumacher · Executive Officer, Director · President and Chief Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Garden State Securities, Inc. (CRD 10083) · Red Bank, New JerseySold in CA, IA, ID, IL, MD, NC, NJ, NY, RI, VA, WA

Signed by Richard Schumacher, President, CEO and Director. Source: SEC Form D, newest notice filed Jan 27, 2016. Read the notice at the SEC.

equity, optionsSEC
Feb 2013$2 MNo. 3Under $2 million

Pressure Biosciences Inc.: Raise no. 3, Feb 2013

Investors in this round

17 investors had bought by the notice of Feb 21, 2013: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Alexander P. Lazarev · Executive Officer
  • Conrad F. Mir · Executive Officer
  • Edmund Y. Ting · Executive Officer
  • Nathan P. Lawrence · Executive Officer
  • Richard T. Schumacher · Executive Officer, Director
  • Jeffrey N. Peterson · Director
  • Kevin A. Pollack · Director
  • Michael S. Urdea · Director
  • Vito J. Mangiardi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$590,000 was received in cash and $1,112,800 was from the conversion of outstanding indebtedness and accrued board of directors' fees.”

Signed by Richard Schumacher, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 21, 2013. Read the notice at the SEC.

equity, optionsSEC
Nov 2009$2 MNo. 2Under $2 million

Pressure Biosciences Inc.: Raise no. 2, Nov 2009

Investors in this round

31 investors had bought by the notice of Apr 1, 2010: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
$100,478
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Alexander P Lazarev · Executive Officer
  • Edmund Y Ting · Executive Officer
  • Matthew B Potter · Executive Officer
  • Nathan P Lawrence · Executive Officer
  • Richard T Schumacher · Executive Officer, Director
  • Alan Donald Rosenson · Director
  • Calvin A Saravis · Director
  • J Donald Payne · Director
  • R Wayne Fritzsche · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Lantern Investments, Inc. (CRD 30996) · Melville, NySold in no state named

Remarks in the notice

  • On fees: “In addition, the finder received warrants to purchase an aggregate of 5,344 shares of Series B Convertible Preferred Stock at $28.80 per share, which warrants expire on August 11, 2012.”

Signed by Richard T. Schumacher, President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Apr 1, 2010. Read the notice at the SEC.

equity, optionsSEC
Feb 2009$2 MNo. 1Under $2 million

Pressure Biosciences Inc.: Raise no. 1, Feb 2009

Investors in this round

35 investors had bought by the notice of Feb 24, 2009: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ma

People named in the notice

  • Alexander Lazarev · Executive Officer
  • Edmund Y Ting · Executive Officer
  • Matthew B Potter · Executive Officer
  • Nathan P Lawrence · Executive Officer
  • Richard T Schumacher · Executive Officer, Director
  • Calvin A Saravis · Director
  • J Donald Payne · Director
  • P Thomas Vogel · Director
  • R Wayne Fritzsche · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard T. Schumacher, President and CEO. Source: SEC Form D, newest notice filed Feb 24, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pressure Biosciences Inc. had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Mar 2019).

    SEC Form D (revenue range) · Mar 2019

  • Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2010; revenue of up to $1 million in 2013; revenue between $1 million and $5 million in 2016; revenue between $1 million and $5 million in 2019.

    SEC Form D (revenue range) · Mar 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Pressure Biosciences Inc.
InvestorKindAmountRoundRoleSource
Alan Ira GoldbergPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2010)SEC Form 3
CSS Llc/ilFund or asset managernot statednot statedHeld Series D and G preferred stock (Form 3, 2012)SEC Form 3
Gregory Gene FreitagPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2010)SEC Form 3
Michael S. UrdeaPersonnot statednot statedHeld Series J preferred stock, director (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 43 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pressure Biosciences Inc.
NameRoleNamed in
Richard P. ThomleyActing Chief Financial OfficerMar 2019
Richard T. SchumacherPresident, Chief Executive Officer, Treasurer and ClerkMar 2019
Richard SchumacherPresident and Chief Executive OfficerJan 2016
Alexander P. LazarevExecutive officerFeb 2013
Conrad F. MirExecutive officerFeb 2013
Edmund Y. TingExecutive officerFeb 2013
Nathan P. LawrenceExecutive officerFeb 2013
Alexander P LazarevExecutive officerApr 2010
Edmund Y TingExecutive officerApr 2010
Matthew B PotterExecutive officerApr 2010
Nathan P LawrenceExecutive officerApr 2010
Richard T SchumacherExecutive officerApr 2010
Alexander LazarevExecutive officerFeb 2009
Jeffrey N. PetersonChairman of the BoardMar 2019
Kevin A. PollackDirectorMar 2019
Michael S. UrdeaChairman of the BoardMar 2019
Richard T. SchumacherPresident, Chief Executive Officer, Treasurer and ClerkMar 2019
Vito J. MangiardiDirectorMar 2019
Richard SchumacherPresident and Chief Executive OfficerJan 2016
Alan Donald RosensonDirectorApr 2010
Calvin A SaravisDirectorApr 2010
J Donald PayneDirectorApr 2010
R Wayne FritzscheDirectorApr 2010
Richard T SchumacherDirectorApr 2010
P Thomas VogelDirectorFeb 2009